[{"orgOrder":0,"company":"Immunis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"IMM01-STEM","moa":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Immunis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immunis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunis \/ Not Applicable"},{"orgOrder":0,"company":"Immunis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"IMM01-STEM","moa":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Immunis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immunis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunis \/ Not Applicable"},{"orgOrder":0,"company":"Immunis","sponsor":"Toray Industries","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"Nalfurafine","moa":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Immunis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Immunis \/ Immunis","highestDevelopmentStatusID":"6","companyTruncated":"Immunis \/ Immunis"},{"orgOrder":0,"company":"Immunis","sponsor":"Springbok","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"IMM01-STEM","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Immunis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Immunis \/ Springbok","highestDevelopmentStatusID":"7","companyTruncated":"Immunis \/ Springbok"},{"orgOrder":0,"company":"Immunis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"IMM01-STEM","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Immunis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Immunis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunis \/ Not Applicable"},{"orgOrder":0,"company":"Immunis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"IMM01-STEM","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Immunis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Immunis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunis \/ Not Applicable"},{"orgOrder":0,"company":"Immunis","sponsor":"Remiges Ventures","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Series A Financing","leadProduct":"IMM01-STEM","moa":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Immunis","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Immunis \/ Remiges Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Immunis \/ Remiges Ventures"}]

Find Clinical Drug Pipeline Developments & Deals by Immunis

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BioAsia
                          Not Confirmed
                          BioAsia
                          Not Confirmed

                          Details : The financing aims to advance the clinical development of IMM01-STEM, which is being evaluated for the treatment of age-related muscle atrophy.

                          Product Name : IMM01-STEM

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          January 11, 2025

                          Lead Product(s) : IMM01-STEM

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Remiges Ventures

                          Deal Size : $25.0 million

                          Deal Type : Series A Financing

                          blank

                          02

                          BioAsia
                          Not Confirmed
                          BioAsia
                          Not Confirmed

                          Details : IMM01-STEM, a secretome product derived from partially differentiated pluripotent stem cells that contains regenerative molecules, being investigated for muscle atrophy related to knee osteoarthritis.

                          Product Name : IMM01-STEM

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          November 19, 2024

                          Lead Product(s) : IMM01-STEM

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          BioAsia
                          Not Confirmed
                          BioAsia
                          Not Confirmed

                          Details : IMM01-STEM, a secretome product derived from partially differentiated pluripotent stem cells that contains regenerative molecules, being investigated for sarcopenic obesity.

                          Product Name : IMM01-STEM

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          September 10, 2024

                          Lead Product(s) : IMM01-STEM

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          BioAsia
                          Not Confirmed
                          BioAsia
                          Not Confirmed

                          Details : Immunis partners with Springbok to evaluate the efficacy of its investigational secretome therapeutic, IMM01-STEM in restoring muscle growth and function in a sarcopenic.

                          Product Name : IMM01-STEM

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          July 25, 2024

                          Lead Product(s) : IMM01-STEM

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Springbok

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          05

                          BioAsia
                          Not Confirmed
                          BioAsia
                          Not Confirmed

                          Details : The partnership aims to focus on the clinical development of TRK-820 (nalfurafine hydrochloride), which is being evaluated for the treatment of Uremic Pruritus.

                          Product Name : TRK-820

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 22, 2024

                          Lead Product(s) : Nalfurafine

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase I

                          Recipient : Toray Industries

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          06

                          BioAsia
                          Not Confirmed
                          BioAsia
                          Not Confirmed

                          Details : IMMUNA (IMM01-STEM) is a secretome product derived from partially differentiated pluripotent stem cells that contains regenerative molecules, which is investigated for the treatment of Muscle Atrophy.

                          Product Name : IMMUNA

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          August 01, 2023

                          Lead Product(s) : IMM01-STEM

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          BioAsia
                          Not Confirmed
                          BioAsia
                          Not Confirmed

                          Details : IMM01-STEM, a secretome product derived from partially differentiated pluripotent stem cells that contains regenerative molecules, in participants with muscle atrophy related to knee osteoarthritis (KOA).

                          Product Name : IMM01-STEM

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          January 24, 2023

                          Lead Product(s) : IMM01-STEM

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank